BMY · Categories · Upgrades
BMY - Analyst upgrades
Bristol-Myers Squibb Company (BMY) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for BMY
- Bristol-Myers upgraded by UBS with a new price targetUBS upgraded Bristol-Myers from Neutral to Buy and set a new price target of $65.00
- Bristol-Myers upgraded by BofA Securities with a new price targetBofA Securities upgraded Bristol-Myers from Neutral to Buy and set a new price target of $61.00
- Bristol-Myers upgraded by Guggenheim with a new price targetGuggenheim upgraded Bristol-Myers from Neutral to Buy and set a new price target of $62.00
- Bristol-Myers upgraded by Jefferies with a new price targetJefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00
- Bristol-Myers upgraded by Daiwa SecuritiesDaiwa Securities upgraded Bristol-Myers from Neutral to Outperform
- Bristol-Myers upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Bristol-Myers from Market Perform to Outperform and set a new price target of $73.00
- Bristol-Myers upgraded by HSBC Securities with a new price targetHSBC Securities upgraded Bristol-Myers from Reduce to Hold and set a new price target of $53.00 from $55.00 previously
- Bristol-Myers Squibb upgraded by Truist Securities with a new price targetTruist Securities upgraded Bristol-Myers Squibb from Hold to Buy and set a new price target of $74.00 from $66.00 previously
- Bristol-Myers upgraded by TruistTruist upgraded Bristol-Myers from Hold to Buy